Advancing HFpEF Treatment with Novel MRAs - Episode 10
Selecting MRAs in HFpEF in Patients With Comorbidities
The panel focuses on balancing efficacy and safety when choosing MRAs for patients with HFpEF with complex comorbid conditions such as CKD and diabetes.
Choosing the right mineralocorticoid receptor antagonist (MRA) for patients with multiple comorbidities remains a clinical challenge. Panelists highlighted that conditions such as diabetes, obesity, and chronic kidney disease can alter drug safety and response.
They emphasized individualized therapy selection, balancing efficacy with renal function and potassium management. Finerenone was noted for its tolerability in patients with metabolic disease, whereas spironolactone remains an option when cost or access is a concern.
Panelists concluded that tailoring MRA use to patient profile, combined with regular follow-up and laboratory monitoring, is key to maximizing benefit and minimizing risk in heart failure with preserved ejection fraction treatment.
